Roger Waltzman is now chief medical officer of Molecular Templates (NASDAQ: [[ticker:MTEM]]). Waltzman comes to the Austin, TX, cancer drug developer from Rgenix, where he was chief medical officer. Molecular Templates develops a class of drugs called engineered toxin bodies. The company’s lead drug candidate, MT-3724, is in Phase 1 testing as a treatment for blood cancers.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
